Related Experiment Video

Updated: Aug 25, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Rising prostate-specific antigen after local therapies have failed: an urgent need for more information

Oliver Sartor

    Clinical Prostate Cancer
    |March 30, 2004
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
    13:19

    Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

    Published on: November 2, 2013

    Related Experiment Videos

    Last Updated: Aug 25, 2026

    A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
    05:19

    A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

    Published on: November 7, 2025

    Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
    13:19

    Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

    Published on: November 2, 2013

    Related Concept Videos

    Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care01:30

    Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care

    A healthcare provider can diagnose a urinary tract infection (UTI) through several methods:Medical History and Symptoms: The provider will take a detailed medical history and ask about symptoms such as frequent urination, burning sensation during urination, and lower abdominal pain.Urinalysis: A clean-catch urine sample is collected in a sterile container and tested for the presence of bacteria, white blood cells (leukocytes), nitrites, blood, and protein. The presence of leukocytes and...
    Disorders of the Male Reproductive System01:20

    Disorders of the Male Reproductive System

    Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
    Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...

    Articles linked to this work by shared authors, journal, and citation graph.

    Normal-Organ Absorbed Dose and Response Assessment in α-Particle Radiopharmaceutical Therapy.

    Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

    Pleomorphic Giant Cell Carcinoma of the Prostate Treated With Lutetium-177 PSMA.

    Case reports in urology·2026

    [177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial.

    Lancet (London, England)·2026

    Detection of Homologous Recombination Repair Gene Mutations by Tumor Tissue and Circulating Tumor DNA Testing in Prostate Cancer in the Phase III PROpel Trial.

    JCO precision oncology·2026

    LuRa: Efficacy and Safety of Radium-223 Following [177Lu]Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer.

    Clinical genitourinary cancer·2026

    Prognostic Value of Interim PSMA-PET Total Tumor Volume for Overall Survival Within ENZA-p, A Randomized Phase 2 Trial of Enzalutamide Versus Enzalutamide Plus [177Lu] Lu-PSMA-617 (ANZUP1901).

    European urology·2026

    Orbital metastasis from prostate cancer: an atypical case of neuroendocrine dedifferentiation during progression from hormone-sensitive to refractory stage.

    Clinical prostate cancer·2005

    Recent trends in surgical treatment of localized prostate cancer.

    Clinical prostate cancer·2005

    Molecular effects of the isoflavonoid genistein in prostate cancer.

    Clinical prostate cancer·2005

    Prostate-specific membrane antigen vaccines: naked DNA and protein approaches.

    Clinical prostate cancer·2005

    Prior estrogen therapy as a predictor of response to subsequent estramustine-based chemotherapy in patients with androgen-independent prostate cancer.

    Clinical prostate cancer·2005

    Quantitative computed tomography perfusion of prostate cancer: correlation with whole-mount pathology.

    Clinical prostate cancer·2005
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us